INO-3107 With Electroporation (EP) in Participants With HPV-6- and/or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)
Completed · Phase 1/Phase 2
Conditions studied: Respiratory Papillomatosis
In brief
This is a Phase 1/2 open-label, multicenter trial to evaluate the safety, tolerability, immunogenicity, and efficacy of INO-3107 in participants with human papilloma virus type 6 (HPV-6) and/or type 11 (HPV-11)-associated recurrent respiratory papillomatosis (RRP). The trial population will include participants who have been diagnosed with either Juvenile-Onset RRP (J-O RRP) as defined by age at first diagnosis \<12 years or with Adult- Onset RRP (A-O RRP) as defined by age at first diagnosis ≥12 years. A safety run-in will be performed with up to six participants with a one week waiting period between each enrolled participant.
Key facts
- Study ID
- NCT04398433
- Run by
- Inovio Pharmaceuticals
- People needed
- 32
- Starts
- 2020-10-07
- Expected to finish
- 2022-12-15
- Last updated by the study team
- 2026-04-14
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Mayo Clinic Arizona — Phoenix, Arizona, United States
- University of California at Davis — Sacramento, California, United States
- Winship at Emory University Hospital Midtown — Atlanta, Georgia, United States
- Johns Hopkins University School of Medicine — Baltimore, Maryland, United States
- Washington University School of Medicine — St Louis, Missouri, United States
- NYU Langone Voice Center — New York, New York, United States
- UNC School of Medicine — Chapel Hill, North Carolina, United States
- Cincinnati Children's Hospital — Cincinnati, Ohio, United States
- University of Cincinnati Medical Center — Cincinnati, Ohio, United States
- UT Southwestern Medical Center — Dallas, Texas, United States
- Baylor College of Medicine — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.